Drug intelligence / Profile preview

PNQ-154

Development stage: Preclinical
Lead developer: Impetis Biosciences
Modality: Small Molecules
Administration: Oral

Overview

PNQ-154 is a small molecule, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK) being developed by Impetis Biosciences. Unlike first-generation covalent BTK inhibitors such as ibrutinib, PNQ-154 is designed to maintain activity in the presence of resistance mutations, such as the C481S mutation, which frequently occur in patients with B-cell malignancies. The drug is intended for oral administration and is currently in the IND-enabling stage for the treatment of ibrutinib-resistant cancers, including diffuse large B-cell lymphoma (DLBCL).

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on PNQ-154.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNQ-154.

Explore the full profile